Acadia Pharmaceuticals | ACAD - Operating Expenses

Stock Price
20.61
Daily Change
-0.66 -3.10%
Monthly
-10.20%
Yearly
17.77%
Q1 Forecast
19.99

Acadia Pharmaceuticals reported $266.6M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
ALKERMES USD 326.44M 1.41B Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Cara Therapeutics USD 4.96M 2.38M Mar/2025
Corcept Therapeutics USD 197.64M 219K Dec/2025
Cytokinetics USD 196.12M 27.43M Dec/2025
Eisai JPY 199.9B 16.22B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
J&J USD 18.97B 2.38B Dec/2025
Moderna USD 1.54B 259M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Prothena USD 42.18M 14.25M Sep/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025